In brief
Researchers are optimistic about a mango-flavored pill, aimed at eradicating intestinal worms that afflict 1.5 billion people globally, showing success in trials.
Researchers have unveiled a promising mango-flavored pill developed to treat intestinal worms, indicating potential breakthroughs in combating parasitic infections that impact around 1.5 billion people worldwide. This new tablet merges two established anti-parasitic medications, demonstrating enhanced effectiveness in eliminating these harmful worms, typically transmitted through contaminated food or water.The infections caused by these parasites—known as soil-transmitted helminths (STHs), including species like whipworm and hookworm—lead to severe gastrointestinal issues, malnutrition, and anemia. The researchers believe this pill could mitigate risks of future drug resistance and improve disease management on a broader scale.In a recent study dubbed "ALIVE," published in the Lancet, the findings suggest that such an innovation could assist heavily affected countries in achieving World Health Organization (WHO) elimination goals. The pill would be administrated either as a singular dose or as multiple doses taken over consecutive days.According to project leader Prof. Jose Muñoz, this approach simplifies mass treatment programs. "It is easy to administer, as it is one single pill," he explained. By combining drugs with different actions, the researchers aim to lower the chance of parasites developing resistance.Currently, treatment options like albendazole are losing efficacy against certain infections. A clinical trial with 1,001 children aged 5-18 in Ethiopia, Kenya, and Mozambique revealed that the mango-flavored pill, paired with ivermectin, was more effective against various types of infections, albeit inconclusive for treating threadworm.Prof. Hany Elsheikha from the University of Nottingham noted this pill could represent a monumental advancement over current treatments for numerous parasites, despite some uncertainties highlighted in the research. "We don't know if the results would be the same for adults...in other parts of the world," he remarked.Regulatory authorities in Europe and Africa have received the trial results, with decisions anticipated by early 2025. Simultaneously, efforts are underway to recruit 20,000 participants for a follow-up trial in Kenya and Ghana. Dr. Stella Kepha, a researcher at Kenya Medical Research Institute involved in the study, acknowledged the pill's significant potential to enhance community health, indicating that further work is essential before its widespread adoption can be realized.
